150 related articles for article (PubMed ID: 15938591)
1. The effect of omeprazole pre-treatment on rafts formed by reflux suppressant tablets containing alginate.
Dettmar PW; Little SL; Baxter T
J Int Med Res; 2005; 33(3):301-8. PubMed ID: 15938591
[TBL] [Abstract][Full Text] [Related]
2. Review article: alginate-raft formulations in the treatment of heartburn and acid reflux.
Mandel KG; Daggy BP; Brodie DA; Jacoby HI
Aliment Pharmacol Ther; 2000 Jun; 14(6):669-90. PubMed ID: 10848650
[TBL] [Abstract][Full Text] [Related]
3. A comparative study on the raft chemical properties of various alginate antacid raft-forming products.
Dettmar PW; Gil-Gonzalez D; Fisher J; Flint L; Rainforth D; Moreno-Herrera A; Potts M
Drug Dev Ind Pharm; 2018 Jan; 44(1):30-39. PubMed ID: 28836872
[TBL] [Abstract][Full Text] [Related]
4. [Alginate-raft preparations in the treatment of acid reflux and heartburn (literature review)].
Mandel KG; Deggi BP; Brodi DA; Jeykobi GI
Eksp Klin Gastroenterol; 2008; (4):64-77. PubMed ID: 19145905
[No Abstract] [Full Text] [Related]
5. Administration of an alginate based gastric reflux suppressant on the bioavailability of omeprazole.
Dettmar PW; Hampson FC; Jain A; Choubey S; Little SL; Baxter T
Indian J Med Res; 2006 Apr; 123(4):517-24. PubMed ID: 16783042
[TBL] [Abstract][Full Text] [Related]
6. Gastroesophageal reflux in pregnancy: a systematic review on the benefit of raft forming agents.
Quartarone G
Minerva Ginecol; 2013 Oct; 65(5):541-9. PubMed ID: 24096290
[TBL] [Abstract][Full Text] [Related]
7. Alginate antacid (Gaviscon DA) chewable tablets reduce esophageal acid exposure in Chinese patients with gastroesophageal reflux disease and heartburn symptoms.
Yuan YZ; Fang JY; Zou DW; Levinson N; Jenner B; Wilkinson J
J Dig Dis; 2016 Nov; 17(11):725-734. PubMed ID: 27622897
[TBL] [Abstract][Full Text] [Related]
8. Clinical and laboratory studies of the antacid and raft-forming properties of Rennie alginate suspension.
Tytgat GN; Simoneau G
Aliment Pharmacol Ther; 2006 Mar; 23(6):759-65. PubMed ID: 16556178
[TBL] [Abstract][Full Text] [Related]
9. [Estimation of efficiency of alginate-raft barrier in treatment of gastroesophageal reflux disease].
Bordin DS; Masharova AA; Firsova LD; Kozhurina TS; Safonova OV
Eksp Klin Gastroenterol; 2008; (6):77-81. PubMed ID: 19334430
[No Abstract] [Full Text] [Related]
10. [pH gradient support and antacid action of gastroesophageal coating agents. In vitro pharmacologic study using a model of "the artificial stomach"].
Vatier J; Vitre MT; Vallot T; Mignon M
Gastroenterol Clin Biol; 1990; 14(5):414-22. PubMed ID: 2163935
[TBL] [Abstract][Full Text] [Related]
11. Rheological investigation of the shear strength, durability, and recovery of alginate rafts formed by antacid medication in varying pH environments.
Elliott BM; Steckbeck KE; Murray LR; Erk KA
Int J Pharm; 2013 Nov; 457(1):118-23. PubMed ID: 24095816
[TBL] [Abstract][Full Text] [Related]
12. Post-prandial reflux suppression by a raft-forming alginate (Gaviscon Advance) compared to a simple antacid documented by magnetic resonance imaging and pH-impedance monitoring: mechanistic assessment in healthy volunteers and randomised, controlled, double-blind study in reflux patients.
Sweis R; Kaufman E; Anggiansah A; Wong T; Dettmar P; Fried M; Schwizer W; Avvari RK; Pal A; Fox M
Aliment Pharmacol Ther; 2013 Jun; 37(11):1093-102. PubMed ID: 23600790
[TBL] [Abstract][Full Text] [Related]
13. Randomized clinical trial: a double-blind, placebo-controlled study to assess the clinical efficacy and safety of alginate-antacid (Gaviscon Double Action) chewable tablets in patients with gastro-oesophageal reflux disease.
Wilkinson J; Wade A; Thomas SJ; Jenner B; Hodgkinson V; Coyle C
Eur J Gastroenterol Hepatol; 2019 Jan; 31(1):86-93. PubMed ID: 30272584
[TBL] [Abstract][Full Text] [Related]
14. [Alginate-containing preparation gaviscon for patients with gastroesophaginal reflux complicated with chronic pancreatitis: pathogenetic substantiation of clinical use prospects].
Uspenskiĭ IuP; Pakhomova IG; Bubiakina VN
Eksp Klin Gastroenterol; 2008; (1):96-101. PubMed ID: 19145860
[No Abstract] [Full Text] [Related]
15. In-vivo anti-reflux and raft properties of alginates.
Lambert JR; Korman MG; Nicholson L; Chan JG
Aliment Pharmacol Ther; 1990 Dec; 4(6):615-22. PubMed ID: 2129648
[TBL] [Abstract][Full Text] [Related]
16. Alginate-antacid combinations: raft formation and gastric retention studies.
Hampson FC; Jolliffe IG; Bakhtyari A; Taylor G; Sykes J; Johnstone LM; Dettmar PW
Drug Dev Ind Pharm; 2010 May; 36(5):614-23. PubMed ID: 19925256
[TBL] [Abstract][Full Text] [Related]
17. An alginate-antacid formulation localizes to the acid pocket to reduce acid reflux in patients with gastroesophageal reflux disease.
Rohof WO; Bennink RJ; Smout AJ; Thomas E; Boeckxstaens GE
Clin Gastroenterol Hepatol; 2013 Dec; 11(12):1585-91; quiz e90. PubMed ID: 23669304
[TBL] [Abstract][Full Text] [Related]
18. Two placebo-controlled crossover studies in healthy subjects to evaluate gastric acid neutralization by an alginate-antacid formulation (Gaviscon Double Action).
Wilkinson J; Abd-Elaziz K; den Daas I; Wemer J; van Haastert M; Hodgkinson V; Foster M; Coyle C
Drug Dev Ind Pharm; 2019 Mar; 45(3):430-438. PubMed ID: 30470147
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of adding sodium alginate to omeprazole in patients with nonerosive reflux disease: a randomized clinical trial.
Manabe N; Haruma K; Ito M; Takahashi N; Takasugi H; Wada Y; Nakata H; Katoh T; Miyamoto M; Tanaka S
Dis Esophagus; 2012 Jul; 25(5):373-80. PubMed ID: 22050449
[TBL] [Abstract][Full Text] [Related]
20. [The experience of usage of alginate contain medication in complex therapy at children with GERD disease].
Shcherbakov PL; Lobanov IuF; Fugol DS; Shilova AV
Eksp Klin Gastroenterol; 2009; (5):81-4. PubMed ID: 20201310
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
